New Releases from NCBI BookshelfNivolumab and Relatlimab (Opdualag): CADTH Reimbursement Review: Therapeutic area: Unresectable or metastatic melanoma [Internet].Nivolumab and Relatlimab (Opdualag): CADTH Reimbursement Review: Therapeutic area: Unresectable or metastatic melanoma [Internet].

By / July 10, 2024

Post Content

New Releases from NCBI BookshelfCannabidiol (Epidiolex): CADTH Reimbursement Recommendation: Indication: Use as adjunctive therapy for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age and older [Internet].Cannabidiol (Epidiolex): CADTH Reimbursement Recommendation: Indication: Use as adjunctive therapy for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age and older [Internet].

New Releases from NCBI BookshelfInfliximab (Remsima SC): CADTH Reimbursement Recommendation: Indication: For the maintenance treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or were intolerant to conventional therapy. Remsima SC should only be used as maintenance therapy after the completion of an induction period with intravenous infliximab [Internet].Infliximab (Remsima SC): CADTH Reimbursement Recommendation: Indication: For the maintenance treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or were intolerant to conventional therapy. Remsima SC should only be used as maintenance therapy after the completion of an induction period with intravenous infliximab [Internet].

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

Registration No: 771800548 Contact Number : +91-8249516996

Publication
Skill Development
Blog Writing

Research
Awareness Camp
Digital Research

Ngo Darpan
Service
Donation

Term and Condition
Privacy Policy
Disclaimer

Scroll to Top

New Releases from NCBI BookshelfNivolumab and Relatlimab (Opdualag): CADTH Reimbursement Review: Therapeutic area: Unresectable or metastatic melanoma [Internet].Nivolumab and Relatlimab (Opdualag): CADTH Reimbursement Review: Therapeutic area: Unresectable or metastatic melanoma [Internet].

Leave a Comment Cancel Reply

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.